Our next-gen hormone antagonist is targeting high-risk patients while expanding into new indications

Hinzugefügt: 2026-05-05

[00:00:00]We have our second asset that we acquired through acquisition of a UK based in London based company, which is a Teverelix. It is a next generation a GnRH or hormone antagonist with a two approved indication in urology in men's health for advanced prostate cancer study with patients with high cardiovascular risk profile and to prevent relapse of acute urinary retention primarily due to benign prostate enlargement.